Patients with IDH1 mutations are thought to comprise secondary GBM as they are enriched for ATRX mutations similar to that found in lower-grade glioma and patients survive for a median survival of 31 months which is consistent with lower-grade glioma (5). The gene discussed is ATRX; the disease is central nervous system cancer.